secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001493152-26-010408
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona reports $71.2M net income in FY 2025; first ZEVASKYN patient treated
---------------------------------------------------------------------------

- First ZEVASKYN commercial patient treated in Dec 2025; net product revenue $2.4M; one patient treated in Q1 2026 with more biopsies collected.
- Total revenue $5.8M including $3.4M license revenue from Taysha milestone; PRV sale net gain $152.4M.
- Net income $71.2M ($1.34 basic EPS) vs loss of $63.7M in 2024; cash $191.4M as of Dec 31, 2025.
- R&D spend decreased to $26.8M; SG&A increased to $65.0M due to commercial transition post-FDA approval.
- Expanding patient access: fourth QTC activated at UTMB Galveston; building launch momentum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315226010408/0001493152-26-010408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315226010408/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-010408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer